Pelareorep Combo Yields Survival Benefit in HR+/HER2– Breast Cancer
Efficacy outcomes including overall survival (OS) were improved when combining pelareorep with paclitaxel for patients with hormone receptor (HR)–positive, HER2-negative advanced or metastatic breast cancer, according to a press release on findings from …